Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2026-03-13 @ 5:07 AM
Study NCT ID:
NCT05686434
Status:
RECRUITING
Last Update Posted:
2023-01-17
First Post:
2023-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | NSCLC, Stage I | View |
Keywords: